BCYC:NSD-Bicycle Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 43.29

Change

+0.94 (+2.22)%

Market Cap

USD 1.12B

Volume

0.13M

Avg Analyst Target

USD 43.43 (+0.32%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+6.68 (+1.54%)

USD175.20B 51.28 41.56
BNTX BioNTech SE

-2.09 (-0.61%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

+0.11 (+0.02%)

USD69.19B 11.68 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.53 (-0.82%)

USD48.20B 24.50 16.63
BGNE BeiGene Ltd

-0.33 (-0.08%)

USD41.72B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+4.15 (+2.51%)

USD30.02B 51.49 39.11
GMAB Genmab A/S

-0.22 (-0.50%)

USD28.07B 71.33 8.17
RPRX Royalty Pharma plc

-0.34 (-0.93%)

USD22.24B 29.66 12.50
ALNY Alnylam Pharmaceuticals Inc

-1.94 (-1.05%)

USD21.89B N/A N/A

ETFs Containing BCYC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 141.17% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 141.17% 94% A 96% A
Trailing 12 Months  
Capital Gain 113.36% 86% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.36% 86% B 85% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 57.15% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.15% 78% C+ 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 55.19% 56% F 32% F
Risk Adjusted Return 103.54% 99% A+ 94% A
Market Capitalization 1.12B 75% C 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1,839.00 1% F 1% F
Price/Book Ratio 7.84 21% F 18% F
Price / Cash Flow Ratio -63.11 93% A 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -57.89% 48% F 26% F
Return on Invested Capital -50.44% 48% F 16% F
Return on Assets -22.14% 56% F 17% F
Debt to Equity Ratio 15.19% 46% F 64% D
Technical Ratios  
Short Ratio 3.79 58% F 44% F
Short Percent 4.10% 60% D- 40% F
Beta -0.34 97% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.